Workflow
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
ABTAbbott(ABT) Benzinga·2025-01-22 19:39

Company Performance - Abbott Laboratories reported fourth-quarter sales of 10.97billion,whichisa7.210.97 billion, which is a 7.2% increase year over year, but it missed the consensus estimate of 11.01 billion [2] - Adjusted diluted earnings per share for Abbott were 1.34,aligningwithanalystestimatesandmanagement′sguidanceof1.34, aligning with analyst estimates and management's guidance of 1.31-1.37,upfrom1.37, up from 1.19 a year ago [2] - For full-year 2025, Abbott projects adjusted EPS of 5.05−5.05-5.25, compared to a consensus of 5.16,withorganicsalesgrowthexpectedat7.55.16, with organic sales growth expected at 7.5%-8.5% and an adjusted operating margin of 23.5%-24.0% [3] Market Movements - Blackboxstocks Inc. shares surged 101% to 3.39 following a 250Ksecuritiespurchaseagreementandpotentialmergeranticipation[9]−AbsciCorporation′ssharesincreasedby26250K securities purchase agreement and potential merger anticipation [9] - Absci Corporation's shares increased by 26% to 4.0450 after Needham initiated coverage with a Buy rating and a 9pricetarget[9]−ImmunoPreciseAntibodiesLtd.sharesrose309 price target [9] - ImmunoPrecise Antibodies Ltd. shares rose 30% to 0.6396 after announcing the development of a new class of GLP-1 therapies [9] - Agilysys, Inc. shares fell 21% to 100.00duetoworse−than−expectedthird−quartersalesresultsandFY25revenueguidancebelowestimates[9]−HepionPharmaceuticals,Inc.sharesplummeted61100.00 due to worse-than-expected third-quarter sales results and FY25 revenue guidance below estimates [9] - Hepion Pharmaceuticals, Inc. shares plummeted 61% to 0.1265 after announcing a 9millionpublicoffering[9]−LisataTherapeutics,Inc.sharesdropped309 million public offering [9] - Lisata Therapeutics, Inc. shares dropped 30% to 2.72 following preliminary cohort data from its Phase 2 Ascend trial [9]